The Influence of Sampling Site When Assessing Glucose Tolerance or Insulin Sensitivity With Oral Glucose Ingestion

October 24, 2016 updated by: Javier Gonzalez, University of Bath

For decades, it has been known that post-meal blood glucose concentrations were associated with the risk of T2D, which was reflected in early diagnostic guidelines. The oral glucose tolerance test (OGTT) has been used since at least 1923 and has remained the most common test for assessing glucose tolerance. Arterial blood (or arterialised blood using heated hand technique) is most appropriate for determining glucose tolerance and insulin sensitivity since this best represents the concentrations of metabolites and hormones that peripheral tissues are exposed to. It is essential to investigate whether venous blood (sometimes used during an OGTT) is representative of arterialised blood during an OGTT, and under different metabolic conditions.

The investigators want to understand whether OGTT-derived insulin sensitivity indices differ from venous and arterialised blood; and 2) investigate whether metabolic status (i.e. rest vs lower-limb exercise) influences the difference between forearm venous and arterialised concentrations of glucose and insulin during an OGTT.

Study Overview

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bath, United Kingdom, BA2 7AY
        • Department for Health, University of Bath

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Aged 18-49 years
  • Able and willing to safely comply with all study procedures
  • Able to provide written informed consent for participation

Exclusion Criteria:

  • Diagnosis of any bleeding disorder or taking medication which impacts blood coagulation
  • The presence of any contraindications to maximal exercise testing, as determined using a physical activity readiness questionnaire (PAR-Q).
  • Any diagnosis of metabolic disease (i.e. cardiovascular disease or type 2 diabetes).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Rest
Remain rested prior to the oral glucose tolerance test
Allowed to watch television or read for one hour prior to oral glucose tolerance test
EXPERIMENTAL: Exercise
Complete exercise prior to the oral glucose tolerance test
One hour of cycling at 50% of maximal power output

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Postprandial plasma glucose concentrations (area under the concentration-time curve)
Time Frame: 120 mins
120 mins
OGTT-derived insulin sensitivity
Time Frame: 120 mins
120 mins

Secondary Outcome Measures

Outcome Measure
Time Frame
Fasting plasma glucose concentrations
Time Frame: 5 mins
5 mins
Fasting plasma insulin concentrations
Time Frame: 5 mins
5 mins
Fasting plasma lactate concentrations
Time Frame: 5 mins
5 mins
Fasting plasma triglyceride concentrations
Time Frame: 5 mins
5 mins
Postprandial plasma lactate concentrations (area under the concentration-time curve)
Time Frame: 120 mins
120 mins
Postprandial plasma triglyceride concentrations (area under the concentration-time curve)
Time Frame: 120 mins
120 mins
Substrate utilization for energy provision
Time Frame: 180 mins
180 mins
Postprandial plasma insulin concentrations (area under the concentration-time curve)
Time Frame: 120 mins
120 mins

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2015

Primary Completion (ACTUAL)

April 1, 2016

Study Completion (ACTUAL)

September 1, 2016

Study Registration Dates

First Submitted

July 28, 2016

First Submitted That Met QC Criteria

August 1, 2016

First Posted (ESTIMATE)

August 2, 2016

Study Record Updates

Last Update Posted (ESTIMATE)

October 25, 2016

Last Update Submitted That Met QC Criteria

October 24, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperglycemia

Clinical Trials on Rest

Subscribe